[go: up one dir, main page]

WO1997032593A2 - Composition contenant des iso-flavonoides et des lignanes - Google Patents

Composition contenant des iso-flavonoides et des lignanes Download PDF

Info

Publication number
WO1997032593A2
WO1997032593A2 PCT/GB1997/000622 GB9700622W WO9732593A2 WO 1997032593 A2 WO1997032593 A2 WO 1997032593A2 GB 9700622 W GB9700622 W GB 9700622W WO 9732593 A2 WO9732593 A2 WO 9732593A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
lignans
flavonoids
iso
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1997/000622
Other languages
English (en)
Other versions
WO1997032593A3 (fr
Inventor
Michael Stafford Morton
Keith Griffiths
Carl Herman Thomas Adlercreutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Energiser PLC
Original Assignee
Energiser PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9604945.7A external-priority patent/GB9604945D0/en
Priority claimed from GBGB9610768.5A external-priority patent/GB9610768D0/en
Application filed by Energiser PLC filed Critical Energiser PLC
Priority to AU21009/97A priority Critical patent/AU2100997A/en
Publication of WO1997032593A2 publication Critical patent/WO1997032593A2/fr
Publication of WO1997032593A3 publication Critical patent/WO1997032593A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/80—Pastry not otherwise provided for elsewhere, e.g. cakes, biscuits or cookies
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/36—Vegetable material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Definitions

  • the present invention relates to a composition and method of treatment useful to combat disease states, such as cancer, especially before such disease states are clinically detectable or alternatively when they are less advanced.
  • the "Western diet” has been considered to be one in which the fat consumption is high, whereas the "fibre” intake is low.
  • the proportion of the total calorific intake related to fat in the more vegetarian-style “Eastern diet” is comparatively low and the "fibre”, and fruit and vegetable content of the diet is high, or high in relation to fat intake (see Yu et al, Int J. Epidemiol 127 : 42-49 (1988)).
  • Western diseases such as cancers of the breast and of the prostrate gland, and also colorectal carcinoma and cardiovascular disease, are associated with fat as a causative factor.
  • the present invention provides a composition to combat cancer (especially breast cancer), benign prostatic hyperplasia, cardiovascular disease and post-menopausal symptoms, said composition being capable of elevating the levels of iso-flavonoids and lignans (eg enterolactone and/or enterodiol) in the body.
  • cancer especially breast cancer
  • benign prostatic hyperplasia cardiovascular disease
  • post-menopausal symptoms said composition being capable of elevating the levels of iso-flavonoids and lignans (eg enterolactone and/or enterodiol) in the body.
  • lignans eg enterolactone and/or enterodiol
  • administration of the composition causes an increase in the amount of available iso-flavonoids and lignans, ie of iso-flavonoids and lignans circulating in the bloodstream.
  • iso-flavonoids we refer to isoflavonic phyto-oestrogens .
  • the daily dosage of said composition is selected so that the levels of iso-flavonoids and lignans (eg enterolactone and/or enterodiol) are maintained at therapeutically useful concentrations.
  • the composition may provide a daily dosage of 10-50 mg iso-flavonoids, conveniently 20-30 mg iso- flavonoids.
  • the composition may further provide a daily dosage of 2-5 mg lignans, conveniently 3-4 mg lignans.
  • composition of the present invention may be used as a prophylactic (ie preventative) measure or may be used to treat, hinder or prevent existing cancer developments. In the latter case, the composition of the present invention maybe used in combination with other conventional treatments, such as radiotherapy for cancer etc.
  • the composition of the present invention is presented in the form of a foodstuff, conveniently in the form of a biscuit or "cookie".
  • the composition may contain a soya-based component and a flaxseed-based or rye-based component as major ingredients; since these components are capable of providing the iso-flavonoids and lignans (such as enterolactone and enterodiol) respectively.
  • the composition further contains rye bran, which in combination with the flaxseed or rye, and soya-based components is particularly efficacious.
  • Alternative ingredients which are also good sources of iso-flavonoids may be used to replace the soya-based component, whilst alternative ingredients which are good sources of enterolactone may be used instead of the flaxseed-based component.
  • Rye is preferred as a source of lignans.
  • the foodstuff will normally also contain other ingredients to produce a palatable product.
  • the micro-flora in the gut of the patient breakdown or otherwise act upon the soya and flaxseed- or rye-based components, producing iso-flavonoids and lignans which are then absorbed and taken up into the bloodstream of the patient.
  • the concentrations of iso-flavonoids and lignans in the patient's bloodstream is deliberately elevated.
  • the composition contains 15% to 35% by weight of a soya based component (for example 20% to 30%, especially about 25% by weight), together with 8% to 16% by weight of a flaxseed based component (for example 11% to 13%, especially about 12% by weight) and /or 6% to 13% by weight of a rye based component (for example 8% to 10%, especially about 9% by weight).
  • the composition provides 20-30 mg iso- flavonoids (preferably substantially genistein and daidzein) and 3-4 mg lignans per day per patient.
  • a 25-30 g cookie made from ingredients including 8-10 g soya and a total of 4-8 g linseed flour and rye bran would provide the required amounts of iso-flavonoids and lignans .
  • the composition of the present invention also contains a significant amount (for example 20-40% of the recommended daily intake, usually approximately 25% of the recommended daily intake) of fibre.
  • a significant amount for example 20-40% of the recommended daily intake, usually approximately 25% of the recommended daily intake
  • rye provides both the lignans required and also the fibre component.
  • the fibre content of the cookie would typically be rye or wheat bran.
  • the bran is believed to prevent the reabsorption of oestrogen by the gut - lowering plasma oestrogens by hindering reabsorption by the enterohepatic circulation.
  • Lower plasma oestrogen may be effective in preventing breast cancer development.
  • the concept relates to the marked differences in the incidence of breast and prostate cancer, clinical BPH (benign prostatic hyperplasia) and cardiovascular disease between the Asian countries where there is little incidence of these diseases, and the Western developed countries of Northern Europe and the USA, where these diseases are, except for BPH, principal killers.
  • the composition essentially increases the levels of iso- flavonoids and lignans in the plasmas of Western people to those concentrations of both as measured in the plasma of Asian people and of lignans in vegetarians.
  • composition could therefore favourably influence
  • iso-flavonoid is genistein, but other iso-flavonoids may also be used. Mention may be made of daidzein, biochanin A and formonentein as being other iso-flavonoids of interest.
  • angiogenesis inhibitor (preventing blood vessels growing out to support tumour growth) .
  • the present invention provides a method of combatting cancer in a human or non-human (preferably mammalian) animal body, said method comprising elevating the levels of iso-flavonoids and lignans (eg enterolactone and/or enterodiol) in said body.
  • iso-flavonoids and lignans eg enterolactone and/or enterodiol
  • the present invention provides a method of relieving postmenopausal symptoms in a human or non-human (preferably mammalian) female animal body, said method comprising elevating the levels of iso- flavonoids and lignans (eg enterolactone and/or enterodiol) in said body.
  • iso- flavonoids and lignans eg enterolactone and/or enterodiol
  • the levels of iso-flavonoids and lignans are elevated in situ in the body to therapeutically useful levels, by the administration of a suitable source, for example a sufficient quantity of alternative or in addition to rye as a source of lignans.
  • a suitable source for example a sufficient quantity of alternative or in addition to rye as a source of lignans.
  • the iso-flavonoid and lignans eg enterolactone and/or enterodiol
  • the iso-flavonoid and lignans may be presented in the form of a foodstuff which is consumed by the patient.
  • iso-flavonoid and lignans eg enterolactone and/or enterodiol
  • lignans eg enterolactone and/or enterodiol
  • the present invention provides the use of soya-components as a source of iso-flavonoids in the manufacture of a medicament to combat cancer, benign prostatic hyperplasia, cardiovascular disease and postmenopausal symptoms.
  • the present invention also provides the use of rye and/or flaxseed components as a source of lignans (eg enterolactone and/or enterodiol) in the manufacture of a medicament to combat cancer, benign prostate hyperplasia, cardiovascular disease and post-menopausal symptoms .
  • lignans eg enterolactone and/or enterodiol
  • composition of embodiments of the present invention are set out in the Examples.
  • EXAMPLE 1 A cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) . Conveniently, a batch of mixture may be made by multiplying the quantities of said ingredients, cooking the mixture in a suitable tray or container, and dividing the mixture into conveniently sized cookies.
  • a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
  • a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
  • a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
  • a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
  • a cookie type composition was produced by blending the ingredients set out in the tableb below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
  • a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
  • a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
  • a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
  • the cookies of the present invention illustrated may have a nutritional content as set out below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention porte sur une composition et une méthode de traitement servant à combattre certains états morbides, tels que le cancer et spécialement avant que lesdits états ne soient cliniquement détectables, ou alors à un stade peu avancé. Ladite composition a le pouvoir d'élever les niveaux d'iso-flavonoïdes (par exemple la génistéine) et de lignanes (par exemple des entérolactones) du corps à des niveaux d'efficacité thérapeutique. Ladite composition qui se présente sous forme d'aliment sous la forme pratique d'un biscuit ou d'un petit gâteau, comporte un constituant de soja, associé à un constituant de graine de lin, et/ou à un constituant de seigle.
PCT/GB1997/000622 1996-03-08 1997-03-10 Composition contenant des iso-flavonoides et des lignanes Ceased WO1997032593A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21009/97A AU2100997A (en) 1996-03-08 1997-03-10 Composition containing iso-flavonoids and lignans

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9604945.7A GB9604945D0 (en) 1996-03-08 1996-03-08 Composition
GB9604945.7 1996-03-08
GB9610768.5 1996-05-23
GBGB9610768.5A GB9610768D0 (en) 1996-05-23 1996-05-23 Composition

Publications (2)

Publication Number Publication Date
WO1997032593A2 true WO1997032593A2 (fr) 1997-09-12
WO1997032593A3 WO1997032593A3 (fr) 1997-10-30

Family

ID=26308892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/000622 Ceased WO1997032593A2 (fr) 1996-03-08 1997-03-10 Composition contenant des iso-flavonoides et des lignanes

Country Status (2)

Country Link
AU (1) AU2100997A (fr)
WO (1) WO1997032593A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0906761A3 (fr) * 1997-10-02 1999-05-19 Archer-Daniels-Midland Company Procédé de préparation et d'utilisation de produits phytochimiques
EP0954984A1 (fr) * 1998-05-04 1999-11-10 Källna Specialprodukter AB Composition diététique contenant des fibres
US6391310B1 (en) 1996-03-13 2002-05-21 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of neurological symptoms
WO2002067700A1 (fr) * 2001-02-26 2002-09-06 Oriola Oy Aliment fonctionnel et son procede de preparation
US6451849B1 (en) 1999-03-30 2002-09-17 Hormos Nutraceutical Oy Ltd. Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol
US6689809B2 (en) 1999-03-30 2004-02-10 Hormos Nutraceutical Oy Ltd. Food additive or product or a pharmaceutical preparation, comprising hydroxymatairesinol
EP1629723A1 (fr) * 2004-08-25 2006-03-01 Oriola, OY Aliment fonctionnel et son utilisation
WO2006072647A1 (fr) * 2005-01-10 2006-07-13 Hormos Medical Ltd. Emploi d'une lignane dans l'élaboration d'une préparation destinée à prévenir ou soulager les symptômes d'une insuffisance en oestrogènes
WO2012131639A1 (fr) 2011-04-01 2012-10-04 Funcional Food Research S.R.L. Aliment fonctionnel pour femme comprenant du trèfle violet
CN108208076A (zh) * 2018-01-09 2018-06-29 广州聚澜健康产业研究院有限公司 一种巧克力舒芙蕾及其制备方法
WO2023068778A1 (fr) * 2021-10-18 2023-04-27 리누 바이오 헬스 엘티디. Composition pour la prévention et le traitement de maladies de la ménopause chez la femme comprenant un élément phytogène en tant que principe actif

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4001905A1 (de) * 1990-01-24 1991-07-25 Wilhelm Menge Verfahren zum herstellen einer backware

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509381B2 (en) 1996-03-13 2003-01-21 Archer Daniels Midland Company Method of preparing and using compositions extracted from vegetable matter for the treatment of neurological conditions
US6518319B1 (en) 1996-03-13 2003-02-11 Archer Daniels Midland Company Method of preparing and using compositions extracted from vegetable matter for the treatment of female symptoms
US6261565B1 (en) 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
US6391309B1 (en) 1996-03-13 2002-05-21 Archer Daniesl Midland Company Method of preparing and using isoflavones for the treatment of female symptoms
US6391310B1 (en) 1996-03-13 2002-05-21 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of neurological symptoms
US6391308B1 (en) 1996-03-13 2002-05-21 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of blood related illnesses
US6395279B1 (en) 1996-03-13 2002-05-28 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of cancer
US6399072B1 (en) 1996-03-13 2002-06-04 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of alcoholism
US6900240B2 (en) 1996-03-13 2005-05-31 Archer-Daniels-Midland Company Method of preparing and using compositions extracted from vegetable matter for the treatment of cancer
EP0906761A3 (fr) * 1997-10-02 1999-05-19 Archer-Daniels-Midland Company Procédé de préparation et d'utilisation de produits phytochimiques
EP1466609A1 (fr) * 1997-10-02 2004-10-13 Archer-Daniels-Midland Company Procédé de préparation et d'utilisation d'isoflavones
EP0954984A1 (fr) * 1998-05-04 1999-11-10 Källna Specialprodukter AB Composition diététique contenant des fibres
US6451849B1 (en) 1999-03-30 2002-09-17 Hormos Nutraceutical Oy Ltd. Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol
US7005447B2 (en) 1999-03-30 2006-02-28 Hormos Nutraceutical Oy Ltd. Food product comprising hydroxymatairesinol
US6689809B2 (en) 1999-03-30 2004-02-10 Hormos Nutraceutical Oy Ltd. Food additive or product or a pharmaceutical preparation, comprising hydroxymatairesinol
WO2002067700A1 (fr) * 2001-02-26 2002-09-06 Oriola Oy Aliment fonctionnel et son procede de preparation
EP1629723A1 (fr) * 2004-08-25 2006-03-01 Oriola, OY Aliment fonctionnel et son utilisation
JP2008526819A (ja) * 2005-01-10 2008-07-24 ホルモス メディカル リミテッド エストロゲン欠乏に関連する症状を予防または改善するための組成物を製造するためのリグナンの使用
WO2006072647A1 (fr) * 2005-01-10 2006-07-13 Hormos Medical Ltd. Emploi d'une lignane dans l'élaboration d'une préparation destinée à prévenir ou soulager les symptômes d'une insuffisance en oestrogènes
WO2012131639A1 (fr) 2011-04-01 2012-10-04 Funcional Food Research S.R.L. Aliment fonctionnel pour femme comprenant du trèfle violet
CN108208076A (zh) * 2018-01-09 2018-06-29 广州聚澜健康产业研究院有限公司 一种巧克力舒芙蕾及其制备方法
WO2023068778A1 (fr) * 2021-10-18 2023-04-27 리누 바이오 헬스 엘티디. Composition pour la prévention et le traitement de maladies de la ménopause chez la femme comprenant un élément phytogène en tant que principe actif

Also Published As

Publication number Publication date
AU2100997A (en) 1997-09-22
WO1997032593A3 (fr) 1997-10-30

Similar Documents

Publication Publication Date Title
Desmawati et al. Phytoestrogens and their health effect
US5498631A (en) Method for treatment of menopausal and premenstrual symptoms
Amin et al. Linum usitatissimum L.(Flaxseed)–A multifarious functional food
US5543146A (en) Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland
Bolla Soybean consumption and health benefits
WO2010025605A1 (fr) Aliment naturel fonctionnel nanométrique et son procédé de traitement
AU2016253140B2 (en) Plant extracts for the treatment of excess weight and obesity
Yu et al. Beneficial health properties of psyllium and approaches to improve its functionalities
CA2627314C (fr) Composition pour le traitement de l'obesite comprenant des extraits de haricots blancs, de haricots rouges et de feuilles de the vert
WO1997032593A2 (fr) Composition contenant des iso-flavonoides et des lignanes
Awulachew The role of wheat in human nutrition and its medicinal value
Zhou et al. Sterols and fat-soluble vitamins
Kahlon et al. Effect of wheat bran fiber and bran particle size on fat and fiber digestibility and gastrointestinal tract measurements in the rat
Mayo A natural approach to menopause
Fouad et al. Nutritional supplement prepared from whole meal wheat flour, soya bean flour, flaxseed and anise seeds for alleviating the menopausal symptoms
Zhou et al. Oats
CN110638038A (zh) 一种用于控制高血糖的医学配方营养代餐粉及其制备方法
US20040202732A1 (en) Composition to promote weight loss
CN109758542A (zh) 具有健胃作用的复合木香油脂肪乳制剂及制备方法与应用
Ahmed et al. Essential minerals and phytic acid in legumes with reference to their nutritive and medicinal properties.
WO2017019213A1 (fr) Composition et procédé pour traiter et soulager les symptômes de bouffées de chaleur chez un sujet de sexe féminin
Finelli et al. Health properties of lycopersicum esculentum
Thompson Role of lignans in carcinogenesis
KR100450055B1 (ko) 두과 식물을 주성분으로 함유하는 체질개선용 식품 조성물및 그로부터 제조되는 식품
EP1161253A1 (fr) Utilisation de fleurs de houblon dans des traitements medicinaux

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1997906264

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWW Wipo information: withdrawn in national office

Ref document number: 1997906264

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97531581

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase